The First and Only FDA-Approved Methotrexate Oral Solution. LEARN MORE

Why TASTE Matters

in pediatric compliance to oral medicine

90% OF PEDIATRICIANS polled reported that a drug’s TASTE and PALATABILITY were the biggest BARRIERS to completing treatment.1

Rejection of unpalatable medications is thought to reflect a BIOLOGICAL PREFERENCE FOR SWEET (and also salty or sour tastes), and rejection of bitterness.1

Compliance with bitter-tasting medications can be a particular problem with children, who are MORE BITTER-SENSITIVE THAN ADULTS.1

Palatable medicines can minimize the LOSS OF MEDICATIONS FROM SPILLAGE OR SPITTING. This means more medication goes where it’s supposed to.2

The First and Only FDA-Approved, Ready-to-use Methotrexate Oral Solution.

For acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients

Sweet Taste

No artificial flavor or dyes.

Accurate Dosing

Based on body surface area.

Easy. Simple. Convenient.

Ready-to-use oral solution—requires no time to prepare, no compounding, no crushing or splitting tablets, and no injections.

Important Safety Information

WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY

Methotrexate can cause the following severe or fatal adverse reactions.
Monitor closely and modify dose or discontinue methotrexate as appropriate.

  • Bone marrow suppression [see Warnings and Precautions (5.1)]
  • Serious infections [see Warnings and Precautions (5.2)]
  • Renal toxicity and increased toxicity with renal impairment [see Warnings and Precautions (5.3)]
  • Gastrointestinal toxicity [see Warnings and Precautions (5.4)]
  • Hepatic toxicity [see Warnings and Precautions (5.5)]
  • Pulmonary toxicity [see Warnings and Precautions (5.6)]
  • Hypersensitivity and dermatologic reactions [see Warnings and Precautions (5.7)]
  • Methotrexate can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated in pregnancy. Consider the benefits and risks of XATMEP and risks to the fetus when prescribing XATMEP to a pregnant patient with a neoplastic disease. Advise females and males of reproductive potential to use effective contraception during and after treatment with XATMEP [see Contraindications (4), Warnings and Precautions (5.9), Use in Specific Populations (8.1, 8.3)].

INDICATIONS

Xatmep is a folate analog metabolic inhibitor indicated for the:

  • management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
  • treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen.

ADDITIONAL IMPORTANT SAFETY INFORMATION

The recommended Xatmep dose is to be taken once weekly. Daily use has resulted in fatal toxicity.

Take Xatmep exactly as your doctor tells you.

An accurate dosing device should always be used. Ask your pharmacist for an accurate dosing device. A household teaspoon is not an accurate dosing device.

Xatmep Oral Solution should not be used if hypersensitive or allergic to methotrexate or any of the ingredients in Xatmep.

Xatmep Oral Solution should not be used during pregnancy in patients with pJIA.

Ask your doctor about the risks to the fetus if you or your partner is taking Xatmep for the treatment of ALL.

Pregnancy should be avoided if either partner is taking Xatmep. Contraception should be used by both females and males while either is taking Xatmep and for 6 months after the last dose taken by females and 3 months after the last dose taken by males.

Xatmep Oral Solution should not be used when nursing.

Methotrexate may affect the ability to have children. Methotrexate may affect menstrual cycles and sperm count.

Discuss vaccinations and immunizations with your doctor prior to receiving them, as they may not be as effective, or should be avoided during methotrexate therapy.

Xatmep may cause severe side effects, including organ toxicity. Organ toxicity may include: bone marrow, kidneys, gastrointestinal, liver, lung, skin, soft tissue and bone. Secondary malignancies may occur. Your doctor will monitor you for signs and symptoms of toxicity during treatment.

Other side effects of methotrexate include:

  • mouth sores
  • diarrhea
  • vomiting
  • abdominal distress
  • fatigue
  • chills
  • fever
  • dizziness
  • decreased resistance to infection
  • leukopenia (decrease in white blood cells)
  • malaise

These are not all the possible side effects of Xatmep. Your doctor or your patient's doctor is the best source of advice about side effects.

Call your doctor immediately if you or your patient has any side effects that concern you or do not go away. 

Tell your doctor about any other medications, including prescription and over-the-counter medications, supplements, vitamins, or herbal remedies you are taking. 

Make sure to visit your doctor regularly.

Keep this and all medications out of the reach of children.

Ask your doctor or pharmacist about proper storage and disposal of dispensing bottles and dosing devices.

See full Prescribing Information for further information, including Boxed Warning.

You are encouraged to report NEGATIVE SIDE EFFECTS to Silvergate Pharmaceuticals at 1-855-379-0383, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.